Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2023 | CAR-T resistance in TP53-mutated B-ALL: a loss of signalling

​​Willem Cox and Willem Cox • 11 Dec 2023
ASH 2023
Acute Lymphoblastic Leukemia Leukemia CAR-T

Willem Cox, MSc, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands, explains why patients with TP53-mutated B-cell acute lymphoblastic leukemia (B-ALL) show high resistance to CAR-T therapy. Leukemia cells do not respond well to CAR-T treatment due to a loss of signaling pathways, underscoring a need for better treatment options for this high-risk patient population. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals